DBV Technologies: Bryan Garnier still a buyer.
(CercleFinance.com) - Today broker Bryan Garnier has reviewed the "biotech" group DBV Technologies, which is down another 4% on the Paris Stock Exchange this morning after the group gave details on its cash level.
Analysts remain optimistic and believe that the group has the means to develop. Maintaining their buy rating on the share - which is one of the broker's best picks, analysts also maintain their target price of 86 euros.
Indeed, DBV has used 86 million in cash over the first nine months of 2017, bringing its current free cash to 170.5 million euros at the end of September. These figures are in line with Bryan Garnier's expectations.
Analysts remain confident, even though they expect a "slight increase" in "cash burn" in 2018, due to the pending filing for the marketing authorisation of Viaskin Peanut, i.e. in mid-2018 according to Bryan Garnier. In addition, the group will form a new commercial department.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
Analysts remain optimistic and believe that the group has the means to develop. Maintaining their buy rating on the share - which is one of the broker's best picks, analysts also maintain their target price of 86 euros.
Indeed, DBV has used 86 million in cash over the first nine months of 2017, bringing its current free cash to 170.5 million euros at the end of September. These figures are in line with Bryan Garnier's expectations.
Analysts remain confident, even though they expect a "slight increase" in "cash burn" in 2018, due to the pending filing for the marketing authorisation of Viaskin Peanut, i.e. in mid-2018 according to Bryan Garnier. In addition, the group will form a new commercial department.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.